series-a
Stage
3
Investors
About
Alchemab develops AI-enabled platforms that use data from resilient human immune responses to discover and develop human-derived antibody therapies for difficult-to-treat diseases.
Explore Alchemab's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.